nsc 65346 has been researched along with Pancreatic Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bastea, LI; Döppler, HR; Hollant, LMA; Reid, EM; Storz, P | 1 |
1 other study(ies) available for nsc 65346 and Pancreatic Neoplasms
Article | Year |
---|---|
Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Histones; Humans; Intracellular Signaling Peptides and Proteins; Mice; Pancreatic Neoplasms; Phosphorylation; Prognosis; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Pyrimidine Nucleosides; Signal Transduction; Survivin; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |